drugset / Trial / NCT07214064

Venetoclax- Augmented Treosulfan-Based Reduced Intensity Conditioning Before Allogeneic Stem Cell Transplantation

NCT07214064

Phase 2 Not yet recruiting 27 enrolled University Hospital Tuebingen
NaSingle-groupOpen-labelTreatment

Summary

Safety and Feasibility of a Venetoclax- Augmented Treosulfan-Based Reduced Intensity Conditioning Before Allogeneic Stem Cell Transplantation in AML, MDS/AML and Higher Risk MDS

Timeline

Start
2026-01
Primary completion
2027-08
Completion
2027-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Fludarabine Small molecule 30 mg/m2
Subject Treosulfan Small molecule 10 g
Subject Venetoclax Small molecule 400 mg